Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact email@example.com.
Interaction between Prediabetes and the ABO Blood Types in Predicting Postsurgical Esophageal Squamous Cell Carcinoma-Specific Mortality: The FIESTA Study
28 Pages Posted: 21 Sep 2018More...
Objectives: We aimed to investigate the interaction between prediabetes and the ABO blood types in predicting esophageal squamous cell carcinoma (ESCC)-specific mortality by analyzing data from the FIESTA study on normal/prediabetic patients with ESCC.
Methods: Total 1857 normal/prediabetic patients with ESCC who underwent three-field lymphadenectomy between January 2000 and December 2010 and survived hospitalization were analyzable, with follow-up beginning in 2000 and ending in 2015.
Results: At the end of the follow-up, there were 1161 survivors and 696 non-survivors. The follow-up time ranged from 0.5 months to 180 months. The cumulative survival rates in normal patients were obviously better than in prediabetic patients. The cumulative survival rates were significantly higher in normal patients than in prediabetic patients for the blood types O and A (Log-rank test P<0.05), while no significance was detected for the blood types B and AB. Adjusted risk estimates for ESCC-specific mortality for prediabetic patients relative to normal patients were statistically significant in the blood type B- group (hazard ratio [HR]: 1.71; 95% confidence interval [CI]: 1.33-2.20; P<0.001), but not in the blood type B group (HR: 1.12; 95% CI: 0.77-1.64; P=0.5544).
Conclusions: Our findings indicate that prediabetes can predict the significant risk of ESCC-specific mortality in patients with the blood types O and A.
Funding Statement: This study was financially supported by the Natural Science Foundation of Fujian Province (grants no. 2016J01503, 2016J01508), the Training Project for Young and Middle-Aged Core Talents of Health System of Fujian Province (grants no. 2015-ZQN-JC-7) and the Ministry of Health P.R. China (WKJ2016-2-05). The funders of this study had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Declaration of Interests: The authors declare that they have no competing interests.
Ethics Approval Statement: The study proposal was approved by Ethics Committee of Fujian Cancer Hospital. All patients gave written informed consent.
Keywords: esophageal squamous cell carcinoma; prediabetes; the ABO blood type; prognosis; the FIESTA study
Suggested Citation: Suggested Citation